“Bimekizumab Cumulative Clinical Benefit in Patients With Moderate to Severe Hidradenitis Suppurativa through 1 Year of the BE HEARD I&II Phase 3 Trials”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s477. https://doi.org/10.25251/skin.8.supp.477.